TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03135210

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open-Chain Leg Exercise
Description: Individuals in the open-chain group will progress through standard mobility progression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Chain Leg Exercise
Description: Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
Study: NCT00708760

Intervention type: BEHAVIORAL
Intervention: paper based training
Description: read selected material, test skills learned in simulator lab

Intervention type: BEHAVIORAL
Intervention: web based training
Description: read and view selected web based material, test skills learned in simulator lab
Study: NCT01230138

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP187
Description: High daily dose of 750mg administered as 250mg TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP187
Description: High daily dose of 750mg administered as 375mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP187
Description: Low daily dose of 500mg FP187 administered as 250mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP187
Description: Oral tablets, up to 3 times daily for 20 weeks.
Study: NCT02265315

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lee Silverman Voice Treatment
Description: Time intensive behavioral treatment for Parkinson's hypophonia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lee Silverman Voice Treatment
Description: Time intensive behavioral treatment for Parkinson's hypophonia

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lee Silverman Voice Treatment
Description: Time intensive behavioral treatment for Parkinson's hypophonia
Study: NCT03250572

Intervention type: DIAGNOSTIC_TEST
Intervention: serum ferritin
Description: serum samples and ferritin ELISA test

Intervention type: DIAGNOSTIC_TEST
Intervention: serum ferritin
Description: serum samples and ferritin ELISA test
Study: NCT02102724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil that contains omega-3 fatty acids
Description: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelcaps that contain 1 gram of oleic sunflower oil
Study: NCT03250572

Intervention type: DIAGNOSTIC_TEST
Intervention: serum ferritin
Description: serum samples and ferritin ELISA test
Study: NCT04007523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Support System
Description: Family members and/or caregivers of patients will receive pagers, and alerts will provide recommendations for daily delirium screening and therapeutic activities. Protocols with associated activities will be provided to family members.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Support System
Description: Family members and/or caregivers of patients will receive pagers, and alerts will provide recommendations for daily delirium screening and therapeutic activities. Protocols with associated activities will be provided to family members.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HELP Support System
Description: A postoperative page will be sent, on behalf of participants, to the on-call HELP staff. The page will request early evaluation and enhanced therapeutic protocols for delirium prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HELP Support System
Description: A postoperative page will be sent, on behalf of participants, to the on-call HELP staff. The page will request early evaluation and enhanced therapeutic protocols for delirium prevention.
Study: NCT03274531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral of hypertensive patients to the attending physician
Description: Immediate referral to the treating physician in case of elevated automated office blood pressure measurements
Study: NCT02220933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD1003 100mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MD1003 100mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03341533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ice packs plus usual post-op analgesia
Description: A 9 inch by 12 inch zip lock bag filled with ice chips, placed inside a cotton pillow case, placed directly on the abdomen. Ice chips will be replaced as they thaw. Monitoring of surgical sites, skin integrity, and comfort with ice pack in place by nursing per current procedural guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual post-op analgesia
Description: Standard post-operative analgesia orders will be followed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual post-op analgesia
Description: Standard post-operative analgesia orders will be followed.
Study: NCT03518385

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound,transvaginal scan
Description: The presence of fluid in the uterine cavity during hormonal stimulation.

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound,transvaginal scan
Description: The presence of fluid in the uterine cavity during hormonal stimulation.
Study: NCT00732147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide acetate
Description: 120 micrograms given subcutaneously before each meal X 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 120 micrograms given subcutaneously before each meal x 3.
Study: NCT03817385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive TMS
Description: rTMS x 10 times

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic GT
Description: robotic gait training for 20 times
Study: NCT03722550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starter Infant Formula, Follow-up Formula, and Growing-up Milk Supplemented With a Blend of Five Human Milk Oligosaccharides
Description: Study formulas are administered orally, ad libitum, from enrollment until 15 months of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starter Infant Formula, Follow-up Formula, and Growing-up Milk Supplemented With a Blend of Five Human Milk Oligosaccharides
Description: Study formulas are administered orally, ad libitum, from enrollment until 15 months of age

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breast-feeding
Description: Exclusive Breast-feeding up to 4 months of age

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Starter Infant Formula, Follow-up Formula, and Growing-up Milk
Description: Standard Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
Study: NCT01371539

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lens
Description: Commercially marketed (France), silicone hydrogel, multifocal contact lens for daily wear use.

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lens
Description: Commercially marketed (France), silicone hydrogel, multifocal contact lens for daily wear use.
Study: NCT02405130

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary epinephrine
Description: after failure of standard therapy patients will treated with epinephrine

Intervention type: OTHER
Group type: OTHER
Intervention: no intracoronary epinephrine
Description: patients will receive standard therapy only
Study: NCT00374881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Morphine low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorbitol+Phenylephrine
Description: Sorbitol+Phenylephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorbitol+Phenylephrine+Morphine
Description: Sorbitol+Phenylephrine+Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorbitol low concentration+Phenylephrine+Morphine
Description: Sorbitol low concentration+Phenylephrine+Morphine
Study: NCT01338831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFA102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFA102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFA102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFA102
Study: NCT00893750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NET Truth Education
Description: Individual Narrative Exposure and Truth Education in Groups

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conflict Resolution and Social Competence Skills
Description: Conflict Resolution and Social Competence Skills in Groups

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Ways of Coping
Description: Methods Collected by Local Teachers to Help Vulnerable Children and Youths in Northern Uganda
Study: NCT04135833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-7711
Description: BPI-7711 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-7711
Description: BPI-7711 180 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 600 mg
Study: NCT02340598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold vest
Description: The lowering of body temperature increases basal metabolic rate
Study: NCT02258321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668 capsule
Study: NCT01109251

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Auto-measure of the tension by an autotensiometer
Description: All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Auto-measure of the tension by an autotensiometer
Description: All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS.
Study: NCT01452607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1005
Description: 200 mg Ebselen oral capsules (SPI-1005), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1005
Description: 200 mg Ebselen oral capsules (SPI-1005), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1005
Description: 200 mg Ebselen oral capsules (SPI-1005), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1005
Description: 200 mg Ebselen oral capsules (SPI-1005), single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg Ebselen oral capsules (SPI-1000), single dose
Study: NCT04225299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOOKAD®
Description: TOOKAD® -VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
Study: NCT02475551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IdeS
Description: Intravenous infusion
Study: NCT01618409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PictureRx card
Description: An illustrated format of medication instructions that includes pictures of the medications and icons to illustrate their purpose
Study: NCT02051946

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retroject Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retroject Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retroject Device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethacrynic acid injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethacrynic acid injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balanced salt solution
Study: NCT02136576

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensodyne
Description: Subjects will be instructed to brush with Sensodyne twice daily (2 minutes each time in the morning and the evening) during the duration of the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crest Cavity Protection & MI Paste Plus
Description: Subjects will be instructed to brush twice daily (2 minutes each time in the morning and the evening) using Crest Cavity Protection toothpaste. They will be instructed to apply MI Paste Plus (CPP-ACP with fluoride) twice daily to the study teeth after brushing their teeth. MI Paste Plus will be applied to the study teeth with a finger.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clinpro 5000
Description: Subjects will be instructed to brush with Clinpro 5000 twice daily (2 minutes each time in the morning and the evening) during duration of the study.
Study: NCT01982851

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural de novo
Description: Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSE
Description: The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSE
Description: The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
Study: NCT01571414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200-mg tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200-mg tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200-mg tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200-mg tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200-mg tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: 600-mg tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: 600-mg tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r)
Description: 400-mg/100-mg tablets twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r)
Description: 400-mg/100-mg tablets twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin (RIF)
Description: 300-mg capsules once a day
Study: NCT02273895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: 0.3 mg/mL, intravenously, once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: 0.3 mg/mL, intravenously, once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: 0.3 mg/mL, intravenously, once
Study: NCT01420445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD001 dose level 1
Description: three times daily / 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD001 dose level 2
Description: three times daily / 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pelargonium sidoides extract
Description: 6-9mL three times daily / 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: three times daily / 7 days
Study: NCT03297385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.
Study: NCT03065244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: Subjects randomized to this arm will receive IVIG 2g/kg over 10-12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Subjects randomized to this arm will receive infliximab 10 mg/kg over 2 hours
Study: NCT03849833

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: cholecalciferol, Vitamin D3
Description: Vitamin D3 as dietary supplement
Study: NCT04448405

Intervention type: BEHAVIORAL
Intervention: Questionnaire for evaluation of confinement on deviant sexual fantasies
Description: Questionnaire for evaluation of confinement on deviant sexual fantasies. Population already followed for deviant fantasies
Study: NCT01285245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kineret
Description: once daily 100 mg of kineret subcutaneously for 8 days
Study: NCT00108160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin Ointment [Treatment]
Description: The impact of the treatment arm versus placebo arm on development of new (recurrent) S. aureus infection will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyethylene Glycol Ointment [Placebo]
Description: The impact of the treatment arm versus placebo arm on development of S. aureus re-infections will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
Study: NCT02922907

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: arabinoxylan rice bran
Description: a proprietary product derived from rice bran treated with extracts from three mushrooms

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for arabinoxylan rice bran
Description: inactive product
Study: NCT03891420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galidesivir
Description: Galidesivir IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV infusion
Study: NCT00680433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine IV will be administered after the administration of the normal anaesthetic agents for ECT.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline (placebo) will be administered after the normal anaesthetic agents in ECT.
Study: NCT04341142

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serological tests will be applied on patients blood sampling
Description: Application of tests on patients' serum
Study: NCT03184350

Intervention type: RADIATION
Group type: OTHER
Intervention: Adjuvant pelvic proton radiation
Description: Patients will receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active raster-scanning pencil beam proton radiation
Study: NCT04576611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: face-to-face protocol
Description: The intervention is based on education (on pain neurophysiology and healthy lifestyle habits) and physical exercise (strength, flexibility, joint mobility and self-massage).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-managed protocol
Description: Subjects of this group receive the same intervention content as the other experimental group, but through a mobile application.
Study: NCT03594279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization
Description: Community Mobilization

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization and Community Incentive
Description: Community Mobilization and Community Incentive

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization and Community Incentive
Description: Community Mobilization and Community Incentive
Study: NCT03556579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A with new UV blocker
Description: Test Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A with new UV blocker
Description: Test Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: Control Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: Control Lens
Study: NCT01951157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Powder for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Powder for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin (PM01183)
Description: Powder for concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin (PM01183)
Description: Powder for concentrate for solution for infusion
Study: NCT02368795

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic Stent
Description: A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Indomethacin 100 mg suppository ten minutes before ERCP